Nagi Bioscience, a pioneering Swiss company specializing in cutting-edge laboratory technologies for alternative model organisms research, announced a strategic partnership with Rhino Bio Inc., a leading distributor for next–generation analytical systems in South Korea. The partnership accelerates Nagi Bioscience’s expansion into the South Korean market, driven by strong demand for its flagship product, SydLab™ One.

Under the agreement, Rhino Bio Inc. will distribute Nagi Bioscience’s cutting-edge laboratory technologies across South Korea, with a primary focus on SydLab™ One. This state-of-the-start laboratory platform is revolutionizing experimental biology by delivering in vivo insights at high throughput. SydLab™ One integrates state-of-the-art robotics, microfluidics, and Artificial Intelligence, harnessing the research power of C. elegans, a model organism pivotal in understanding complex biological processes for over sixty years.  The platform is currently driving breakthroughs in aging, neurodegeneration, metabolic diseases, and other critical research areas across Europe and North America.

“Our partnership with Rhino Bio Inc. marks an exciting milestone in Nagi Bioscience’s growth strategy as we expand into the dynamic South Korean market,” said Matteo Cornaglia, CEO of Nagi Bioscience. “The high demand for SydLab™ One demonstrates the growing need for advanced, ethical, and high-throughput research solutions. We are confident that Rhino Bio’s strong local presence and industry expertise will accelerate scientific discoveries and empower researchers across South Korea.”

With over a decade of experience in distributing advanced life science instruments, Rhino Bio Inc. has built a strong reputation as a trusted partner for high-performance research tools in both academic and biotech sectors. “We are very pleased to be able to offer Nagy Bioscience’s innovative SydLab™ One in Korea and very excited to help Korean researchers in the field of aging and neurodegenerative diseases go a step forward.” stated Dennis Ko, President of Sales at Rhino Bio Inc.

The strategic partnership between Nagi Bioscience and Rhino Bio Inc. underscores a shared vision of advancing scientific breakthroughs with cutting-edge technologies that enhance efficiency and reproducibility. As South Korea continues to grow as a global hub for scientific innovation, the introduction of the SydLab™ One platform will empower researchers to accelerate discoveries in critical areas such as drug discovery, early toxicology, and aging. By combining Rhino Bio Inc.’s extensive distribution network and industry expertise with Nagi Bioscience’s pioneering technology, the partnership is set to be a catalyst for innovation supporting research projects tackling pressing biological challenges.